Search

Your search keyword '"Mesfin, Yonatan M."' showing total 6 results
Start Over Author "Mesfin, Yonatan M."
6 results on '"Mesfin, Yonatan M."'

1. Trends and social determinants of the obesity epidemic among reproductive-age women in ten Asian countries

Author

Thapa, Subash, Ahmed, Kedir Y., Bizuayehu, Habtamu Mellie, Huda, M. Mamun, Chalise, Binaya, Bore, Meless G., Belachew, Sewunet Admasu, Hassen, Tahir A., Amsalu, Erkihun, Shifti, Desalegn Markos, Seid, Abdulbasit, Mesfin, Yonatan M., Tegegne, Teketo Kassaw, Dadi, Abel F., Odo, Daniel Bogale, Kibret, Getiye Dejenu, Ketema, Daniel Bekele, Kassa, Zemenu Yohannes, Anyasodor, Anayochukwu E., Mahmood, Shakeel, Astawesegn, Feleke Hailemichael, and Ross, Allen G.

Published
2024
Full Text
View/download PDF

2. Intimate partner violence and childhood health outcomes in 37 sub-Saharan African countries: an analysis of demographic health survey data from 2011 to 2022

Author

Dadi, Abel F, Ahmed, Kedir Y, Berhane, Yemane, Bizuayehu, Habtamu Mellie, Tesema, Getayeneh Antehunegn, Hassen, Tahir A, Kibret, Getiye Dejenu, Ketema, Daniel Bekele, Bore, Meless G, Belachew, Sewunet Admasu, Amsalu, Erkihun, Nhassengo, Sergio, Shifti, Desalegn Markos, Seid, Abdulbasit, Mesfin, Yonatan M, Tegegne, Teketo Kassaw, Odo, Daniel Bogale, Kassa, Zemenu Yohannes, Thapa, Subash, Kidane, Eshetu Girma, Desyibelew, Hanna Demelash, Misganaw, Awoke, Zeleke, Berihun M, Bolarinwa, Obasanjo Afolabi, and Ross, Allen G

Published
2024
Full Text
View/download PDF

3. Population modifiable risk factors associated with neonatal mortality in 35 sub-Saharan Africa countries: analysis of data from demographic and health surveys

Author

Ahmed, Kedir Y., Thapa, Subash, Hassen, Tahir A., Tegegne, Teketo Kassaw, Dadi, Abel F., Odo, Daniel Bogale, Bizuayehu, Habtamu Mellie, Shifti, Desalegn Markos, Belachew, Sewunet Admasu, Kibret, Getiye Dejenu, Ketema, Daniel Bekele, Kassa, Zemenu Yohannes, Amsalu, Erkihun, Bore, Meless G., Seid, Abdulbasit, Mesfin, Yonatan M., Kibret, Kelemu Tilahun, Huda, M. Mamun, Mahmood, Shakeel, Anyasodor, Anayochukwu E., and Ross, Allen G.

Published
2024
Full Text
View/download PDF

4. Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies.

Author

Mesfin, Yonatan M, Blais, Joseph E, Kibret, Kelemu Tilahun, Tegegne, Teketo Kassaw, Cowling, Benjamin J, and Wu, Peng

Subjects
*VACCINATION status, *MOLNUPIRAVIR, *COVID-19 treatment, *ANTIVIRAL agents, *COVID-19 vaccines
Abstract

Objective To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods Observational studies of nirmatrelvir/ritonavir or molnupiravir compared to no antiviral drug treatment for COVID-19 in non-hospitalized adults with data on vaccination status were included. We searched MEDLINE, EMBASE, Scopus, Web of Science, WHO COVID-19 Research Database and medRxiv for reports published between 1 January 2022 and 8 November 2023. The primary outcome was a composite of hospitalization or mortality up to 35 days after COVID-19 diagnosis. Risk of bias was assessed with ROBINS-I. Risk ratios (RR), hazard ratios (HR) and risk differences (RD) were separately estimated using random-effects models. Results We included 30 cohort studies on adults treated with nirmatrelvir/ritonavir (n  = 462 279) and molnupiravir (n  = 48 008). Nirmatrelvir/ritonavir probably reduced the composite outcome (RR 0.62, 95%CI 0.55–0.70; I 2 = 0%; moderate certainty) with no evidence of effect modification by vaccination status (RR P subgroup = 0.47). In five studies, RD estimates against the composite outcome for nirmatrelvir/ritonavir were 1.21% (95%CI 0.57% to 1.84%) in vaccinated and 1.72% (95%CI 0.59% to 2.85%) in unvaccinated subgroups. Molnupiravir may slightly reduce the composite outcome (RR 0.75, 95%CI 0.67–0.85; I 2 = 32%; low certainty). Evidence of effect modification by vaccination status was inconsistent among studies reporting different effect measures (RR P subgroup = 0.78; HR P subgroup = 0.08). In two studies, RD against the composite outcome for molnupiravir were −0.01% (95%CI −1.13% to 1.10%) in vaccinated and 1.73% (95%CI −2.08% to 5.53%) in unvaccinated subgroups. Conclusions Among cohort studies of non-hospitalized adults with COVID-19, nirmatrelvir/ritonavir is effective against the composite outcome of severe COVID-19 independent of vaccination status. Further research and a reassessment of molnupiravir use among vaccinated adults are warranted. Registration PROSPERO CRD42023429232. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results